Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01968109 · ClinicalTrials.gov registry record · Phase 1
An Investigational Immuno-therapy Study to Assess the Safety, Tolerability and Effectiveness of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors
A Phase 1 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 1,482
- Enrollment target
NCT01968109 is a Phase 1 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 1,482 participants.
The verdict
NCT01968109, a Phase 1 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 1,482 participants
- Enrollment target
Study Summary
The purpose of the study is to assess the safety, tolerability and effectiveness of experimental medication BMS-986016 administered alone and in combination with nivolumab in patients with solid tumors that have spread and/or cannot be removed by surgery. The following tumor types are included in this study: Non-Small Cell Lung Cancer (NSCLC), gastric cancer, hepatocellular carcinoma, renal cell carcinoma, bladder cancer, squamous cell carcinoma of the head and neck, and melanoma, that have NOT previously been treated with immunotherapy. NSCLC and melanoma that HAVE previously been treated with immunotherapy.
Interventions
- BIOLOGICAL Nivolumab
- BIOLOGICAL Relatlimab
- BIOLOGICAL BMS-986213
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,482 participants |
| Start Date | 2013-11-05 |
| Est. Completion | 2025-02-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01968109
The ClinicalTrials.gov registry entry for NCT01968109 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 1,482 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Nivolumab is the first listed.
NCT01968109 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01968109 about?
NCT01968109 is a clinical study titled "An Investigational Immuno-therapy Study to Assess the Safety, Tolerability and Effectiveness of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors". The purpose of the study is to assess the safety, tolerability and effectiveness of experimental medication BMS-986016 administered alone and in combination with nivolumab in patients with solid tumors that have spread and/or cannot be removed by surgery. The following tumor types are included in t...
What is the current status of trial NCT01968109?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 1,482 participants. The study started on 2013-11-05. Estimated completion is 2025-02-03.
What interventions are being tested in trial NCT01968109?
The interventions under investigation include: Nivolumab (BIOLOGICAL), Relatlimab (BIOLOGICAL), BMS-986213 (BIOLOGICAL).
Who is sponsoring clinical trial NCT01968109?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.